Girendra Hoskere, MD
Pulmonary Disease · Bristol, TNNPI 1710970793
Payments from drug & device makers
Across 947 payments — averaging $301.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$249K
- Regeneron Healthcare Solutions, Inc.$11K
- Intuitive Surgical$11K
- Amgen$5K
- GSK$3K
- Boehringer Ingelheim$1K
- plus $5K from 32 others
What the payments were for
- Consulting fees$9450%
- Speaking & faculty fees$242,51285%
- Travel & lodging$16,2576%
- Food & beverage$19,6467%
- Education$5,8192%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 414 | $248,744 |
| Regeneron Healthcare Solutions, Inc. | 37 | $11,386 |
| Intuitive Surgical | 21 | $10,543 |
| Amgen | 27 | $5,309 |
| GSK | 152 | $2,555 |
| Boehringer Ingelheim | 59 | $1,460 |
| Actelion Pharmaceuticals US, Inc. | 44 | $1,023 |
| Mallinckrodt Hospital Products Inc. | 18 | $450 |
| Sanofi | 19 | $397 |
| Grifols USA, LLC | 18 | $370 |
| Baxter Healthcare | 13 | $316 |
| Sunovion Pharmaceuticals Inc. | 19 | $270 |
| Merck | 11 | $269 |
| United Therapeutics Corporation | 5 | $258 |
| Jazz Pharmaceuticals Inc. | 9 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $221 |
| Mylan Specialty L.p. | 12 | $188 |
| Insmed, Inc. | 7 | $177 |
| Viatris Specialty LLC | 6 | $126 |
| Portola Pharmaceuticals, LLC | 5 | $108 |
| Philips North America LLC | 5 | $88 |
| ANI Pharmaceuticals, Inc. | 2 | $69 |
| Inogen, Inc. | 3 | $65 |
| Verona Pharma, Inc. | 3 | $62 |
| Mallinckrodt Enterprises LLC | 3 | $60 |
| Pfizer | 3 | $56 |
| La Jolla Pharmaceutical Company | 2 | $53 |
| Circassia Inc. | 4 | $48 |
| Genentech USA, Inc. | 3 | $41 |
| Novartis | 2 | $40 |
| Shionogi Inc | 2 | $37 |
| Harmony Biosciences LLC | 2 | $35 |
| Johnson & Johnson | 3 | $33 |
| Electromed, Inc. | 2 | $29 |
| Olympus America Inc. | 1 | $20 |
| Resmed Corp | 1 | $19 |
| ZOLL Respicardia, Inc. | 1 | $18 |
| Pulmonx Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$162,328
- TEZSPIRE$43,644
- AIRSUPRA$34,758
- DUPIXENT$10,582
- Da Vinci Surgical System$10,269
- SYMBICORT$3,816
- TAGRISSO$641
- NUCALA$350
- BREZTRI AEROSPHERE$118
- XYREM$100
How this compares
$285,193 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $18,900 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $17,136 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $11,611 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $990 |
| Prednisone | 23 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $2,555 | $18,90026 claims |
| AstraZenecaBreztri Aerosphere | $248,744 | $17,13623 claims |
| Boehringer IngelheimStiolto Respimat | $1,460 | $11,61113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Bristol
- Fabien MaldonadoNashville$2.5M
- Aaron MilstoneFranklin$2.4M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Clyde SouthwellHendersonville$801K
- Krishnendu BhadraChattanooga$631K
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.